Integrating treatments for methamphetamine abuse: A psychosocial perspective

被引:83
作者
Huber, A
Ling, W
Shoptaw, S
Gulati, V
Brethen, P
Rawson, R
机构
[1] LOS ANGELES ADDICT TREATMENT RES CTR,LOS ANGELES,CA 90025
[2] W LOS ANGELES VET ADM MEDICAT DEV RES UNIT,LOS ANGELES,CA
[3] UNIV CALIF LOS ANGELES,ALCOHOLISM & ADDICT MED SERV,LOS ANGELES,CA 90024
关键词
D O I
10.1300/J069v16n04_04
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The recent West Coast experience with increased methamphetamine use is showing signs of spreading to other parts of the US. The risk of corresponding medical and psychosocial problems has led to a call to action at the highest levels of government. The next few years will likely witness a substantial increase in treatment research on methamphetamine abuse/dependence, with particular emphasis on the development and application of novel pharmacotherapies. The evaluation of these agents presupposes that we understand the clinical syndrome resulting from chronic methamphetamine use. To establish a clear picture of the biological and psychological sequellae of methamphetamine use, we compare two cohorts (500 methamphetamine and 224 cocaine users) treated at the same outpatient clinic over the past nine years, using identical manualized treatments. The results suggest that while there are important differences in group characteristics and drug effects, the total response to treatment was quite comparable.
引用
收藏
页码:41 / 50
页数:10
相关论文
共 12 条
[1]  
CUNNINGHAM J, 1995, TRENDS REGIONAL VARI
[2]  
Frosch D., 1996, J SUBST ABUSE TREAT, V13, P1
[3]  
HEISCHOBER B, 1991, NIDA RES MONOGR, V115, P60
[4]   Integration of research in pharmacotherapy for addictive disease: Where are we? Where are we going? [J].
Ling, W ;
Shoptaw, S .
JOURNAL OF ADDICTIVE DISEASES, 1997, 16 (04) :83-102
[5]   BREAK-POINTS ON A PROGRESSIVE RATIO SCHEDULE REINFORCED BY INTRAVENOUS COCAINE INCREASE FOLLOWING DEPLETION OF FOREBRAIN SEROTONIN [J].
LOH, EA ;
ROBERTS, DCS .
PSYCHOPHARMACOLOGY, 1990, 101 (02) :262-266
[6]  
RAWSON R A, 1991, Journal of Addictive Diseases, V11, P97
[7]  
Rawson R. A., 1989, NEUROBEHAVIORAL TREA
[8]  
RITZ MC, 1989, J PHARMACOL EXP THER, V248, P1010
[9]  
ROBERTS DS, 1992, NIDA RES MONOGR, V199, P136
[10]  
SHOPTAW S, 1994, J ADDICT DIS, V13, P129